Preferences of patients and health professionals for route and frequency of administration of biologic agents in the treatment of rheumatoid arthritis

Patient Preference and Adherence

Volumn 8, Issue , 2014, Pages 93-99

  Huynh, Tuan Khai ^a,b   Østergaard, Ann ^c   Egsmose, Charlotte ^c   Madsen, Ole Rintek ^c  

^a FREDERIKSBERG HOSPITAL   (Denmark)

^b HILLERØD HOSPITAL   (Denmark)

^c GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Biologic treatment; Infusion; Rheumatology; Subcutaneous injection

Indexed keywords

ABATACEPT; ADALIMUMAB; BIOLOGICAL PRODUCT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; TOCILIZUMAB;

ADULT; ARTICLE; CONTROLLED STUDY; DENMARK; DOSAGE SCHEDULE COMPARISON; DRUG SAFETY; HEALTH PRACTITIONER; HOME CARE; HUMAN; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; NURSE; OUTPATIENT DEPARTMENT; PATIENT PREFERENCE; PATIENT TRANSPORT; PHYSICIAN; QUESTIONNAIRE; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; SELF INJECTION; TREATMENT DURATION;

EID: 84892883607     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S55156     Document Type: Article

References (26)

1. Alamanos Y, Voulgari PV, Drosos AA. Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology criteria: a systematic review. Semin Arthritis Rheum. 2006;36(3):182-188.
2. Gabriel SE, Michaud K. Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis Res Ther. 2009;11(3):229.
3. Keystone EC, Smolen J, van Riel P. Developing an effective treatment algorithm for rheumatoid arthritis. Rheumatology (Oxford). 2012;51 Suppl 5:v48-v54.
4. Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010;69(6): 964-975.
5. Choy EH, Kavanaugh AF, Jones SA. The problem of choice: current biologic agents and future prospects in RA. Nat Rev Rheumatol. 2013;9(3):154-163.
6. Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012;64(5):625-639.
7. Pierreisnard A, Issa N, Barnetche T, Richez C, Schaeverbeke T. Meta-analysis of clinical and radiological efficacy of biologics in rheumatoid arthritis patients naive or inadequately responsive to methotrexate. Joint Bone Spine. 2013;80(4):386-392.
8. Aaltonen KJ, Virkki LM, Malmivaara A, Konttinen YT, Nordström DC, Blom M. Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis. PLoS One. 2012;7(1):e30275.
9. Hetland ML, Christensen IJ, Tarp U, et al; All Departments of Rheumatology in Denmark. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum. 2010;62(1):22-32.
10. Montgomery AA, Fahey T. How do patients' treatment preferences compare with those of clinicians? Qual Health Care. 2001;10 Suppl 1: i39-i43.
11. Yazici Y, McMorris BJ, Darkow T, Rosenblatt LC. Patient and physician perception of the infusion process of the biologic agents abatacept, infliximab, and rituximab for the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2009;27(6):907-913.
12. Pullar T, Wright V, Feely M. What do patients and rheumatologists regard as an 'acceptable' risk in the treatment of rheumatic disease? Br J Rheumatol. 1990;29(3):215-218.
13. van Hulst LT, Kievit W, van Bommel R, van Riel PL, Fraenkel L. Rheumatoid arthritis patients and rheumatologists approach the decision to escalate care differently: results of a maximum difference scaling experiment. Arthritis Care Res (Hoboken). 2011;63(10):1407-1414.
14. Kennedy T, McCabe C, Struthers G, et al; British Society for Rheumatology Standards, Guidelines and Audit Working Group (SGAWG). BSR guidelines on standards of care for persons with rheumatoid arthritis. Rheumatology (Oxford). 2005;44(4):553-556.
15. Kirwan JR, Hewlett SE, Heiberg T, et al. Incorporating the patient perspective into outcome assessment in rheumatoid arthritis - progress at OMERACT 7. J Rheumatol. 2005;32(11):2250-2256.
16. Scarpato S, Antivalle M, Favalli EG, et al; RIVIERA co-authors. Patient preferences in the choice of anti-TNF therapies in rheumatoid arthritis. Results from a questionnaire survey (RIVIERA study). Rheumatology (Oxford). 2010;49(2):289-294.
17. Williams EL, Edwards CJ. Patient preferences in choosing anti-TNF therapies-R1. Rheumatology (Oxford). 2006;45(12):1575-1576.
18. Chilton F, Collett RA. Treatment choices, preferences and decision-making by patients with rheumatoid arthritis. Musculoskeletal Care. 2008;6(1):1-14.
19. Fraenkel L, Fried TR. Individualized medical decision making: necessary, achievable, but not yet attainable. Arch Intern Med. 2010;170(6):566-569.
20. Fraenkel L, McGraw S. What are the essential elements to enable patient participation in medical decision making? J Gen Intern Med. 2007;22(5):614-619.
21. Cunha-Miranda L, Costa L, Ribeiro JS. NEAR study: Needs and Expectations in Rheumatoid ARthritis - do we know our patients needs? Acta Reumatol Port. 2010;35(3):314-323.
22. Ho M, Lavery B, Pullar T. The risk of treatment. A study of rheumatoid arthritis patients' attitudes. Br J Rheumatol. 1998;37(4):459-460.
23. Marshall NJ, Wilson G, Lapworth K, Kay LJ. Patients' perceptions of treatment with anti-TNF therapy for rheumatoid arthritis: a qualitative study. Rheumatology (Oxford). 2004;43(8):1034-1038.
24. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Patient preferences for treatment: report from a randomised comparison of treatment strategies in early rheumatoid arthritis (BeSt trial). Ann Rheum Dis. 2007;66(9):1227-1232.
25. Martin RW, Head AJ, René J, et al. Patient decision-making related to antirheumatic drugs in rheumatoid arthritis: the importance of patient trust of physician. J Rheumatol. 2008;35(4):618-624.
26. Curtis JR, Chen L, Harrold LR, Narongroeknawin P, Reed G, Solomon DH. Physician preference motivates the use of anti-tumor necrosis factor therapy independent of clinical disease activity. Arthritis Care Res (Hoboken). 2010;62(1):101-107.